With the discovery of the innate repair receptor (IRR), Araim has identified a target for activating tissue repair and recovery from inflammation and other injuries. Our lead compound, ARA 290, a first-in-class synthetic peptide, is being developed to help address devastating injuries and chronic diseases underserved by current therapies, through its activation of this platform technology.
Our near-term clinical development program is focused on evaluating the ability of ARA 290 to improve the lives of patients suffering from neuropathic and retinal diseases, where the underlying pathophysiological drivers of disease—insufficient control of inflammatory signaling, insufficient activation of repair processes—remain ongoing and active. Our development program is most advanced in neuropathic pain and disease modification indications, both in sarcoidosis and in diabetes.
ARA 290 has been granted 4 orphan designations, including US and EU orphan designation for the treatment of sarcoidosis, US orphan and fast track designation for the treatment of neuropathic pain in sarcoidosis, and US orphan designation for treatment to increase survival and improve functioning of pancreatic islet cells following transplantation.